Dr. John Cush RheumNow
2 years 10 months ago
Effective Treatments for Rheumatoid Arthritis ILD
The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence.
https://t.co/qJBeM0jdom https://t.co/vdhcHOvHBI
Dr. John Cush RheumNow
2 years 10 months ago
Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab
Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups.
https://t.co/uhlnpmLwoP https://t.co/NRW0PlD43a
We have become accustomed to the 60/40/20% rule for the outcome of ACR 20/50/70 respectively for biologics and targeted synthetic DMARDs. When a new agent is launched, we look out for the treatment response with much anticipation if it will be higher or lower than the benchmark we expect.
Dr. John Cush RheumNow
2 years 10 months ago
Undiagnosed IBD in AxSpA
Dr. Eric Dein (Summit, New Jersey) discusses Abstract #0495 presented at the ACR 2023 Convergence meeting in San Diego.
https://t.co/QAC6fhSQ7Q https://t.co/BxNQwQ9nwc
Dr. John Cush RheumNow
2 years 10 months ago
The impact of SGLT2-inhibitor on SLE outcomes
SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors.
https://t.co/hyyMVQg3xV https://t.co/fLxh0vlTze
Dr. John Cush RheumNow
2 years 10 months ago
Are Rheumatologists doing Enough for Cervical Cancer?
Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients.
https://t.co/VFobM0T3u7 https://t.co/L45N3tsTdN
Dr. John Cush RheumNow
2 years 10 months ago
Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/91PtvQfoIr https://t.co/ZjYCVP5lqG
Dr. John Cush RheumNow
2 years 10 months ago
Long term F/U of early RA, T2T RCTs (n 1616) finds excess mortality > 10yrs for BeST (SMR 1.32) & IMPROVED (SMR 1.33) RCTs; highest in ACPA+ smokers (SMR 2.80 & 2.14); Cancer main cause. SMR incr 34% & 13% for ea 1 pt incr in DAS https://t.co/2DdHMGIlOk https://t.co/7bnCOzB8vd
Dr. John Cush RheumNow
2 years 10 months ago
Infections During Treatment of GPA with Rituximab
Dr. Richard Conway (Dublin, Ireland) discusses abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/eKi3KExEnk https://t.co/b9G9w5e9tc
Dr. John Cush RheumNow
2 years 10 months ago
Watch and Weigh In: Upadacitinib for Pain: Is That Real?
Dr. David Liew reports on abstract 0429 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/AbD9UpXQfY https://t.co/iRgUnNInuD
In this week's podcast, Dr. Jack Cush reviews the ACR Convergence 2023 meeting and proposes how to best learn at your next large medical meeting.
Dr. John Cush RheumNow
2 years 10 months ago
Computer Vision: Is It Ready for RA Assessment?
Dr. David Liew reports on abstract 0402 and 1293 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/4rQDjFXjH2 https://t.co/8FM40kh3bw
